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with Functional Outcomes in Good-Grade PatientsJustin Wang1, Naif M. Alotaibi1,2, Muhammad Ali Akbar1, Oliver G.S. Ayling3, George M. Ibrahim1,
R. Loch Macdonald1,4, SAHIT collaborators*-BACKGROUND: Transient loss of consciousness (LOC)
is one of the most common presentations of aneurysmal
subarachnoid hemorrhage (SAH) and may be an indicator
of early brain injury. In this study, we examined the asso-
ciation of LOC and functional outcomes in patients with
good-grade SAH.
-METHODS: We searched the Subarachnoid Hemorrhage
International Trialists Repository for patients who pre-
sented with LOC at ictus of SAH. A propensity score
analysis was performed on good-grade patients (defined as
World Federation of Neurosurgical Societies grade 1e3) to
balance selected covariates between those with and
without LOC. The primary outcome was Glasgow Outcome
Score (GOS) at 3 months (with poor outcome defined as a
GOS of 1e3). Secondary outcomes were delayed cerebral
ischemia (DCI), rebleed, length of hospital stay, and time to
death.
-RESULTS: A propensity score-matching algorithm iden-
tified 336 patients (168 with and 168 without LOC at ictus).
The proportion of patients with poor functional outcome at
3 months was significantly higher in the cohort with LOC at
ictus compared with the matched cohort without LOC at
ictus (30% vs. 19%; P [ 0.02). There was a nonsignificant
trend toward greater mortality in the patients with LOC at
ictus (19% vs. 13%; P [ 0.14). There were no significantKey words
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308 www.SCIENCEDIRECT.com WORLD NEUdifferences in the secondary outcomes between the 2
cohorts.
-CONCLUSIONS: LOC at ictus of SAH is associated with a
higher rate of unfavorable functional outcomes but not of
mortality, DCI, or rebleed in patients with good-grade SAH.
Future studies should further investigate the putative
mechanisms through which LOC mediates early brain
injury in SAH.INTRODUCTIONntracranial aneurysmal rupture, the most common cause of
nontraumatic subarachnoid hemorrhage (SAH), carries aImortality rate as high as 67% in the ﬁrst few months after
rupture.1 A signiﬁcant proportion of the patients who do survive
are left with signiﬁcant disability and loss of independence.
Almost 30% of survivors have moderate to severe disabilities
afterward, and approximately 65% never return to the same
quality of life that they enjoyed before SAH.2 Prognostication in
SAH is essential, inﬂuencing clinical decisions on initial
management, monitoring, and duration of stay in the intensive
care unit. Known prognostic factors associated with worse
outcome include, but are not limited, to increasing patient age,
worsening neurologic grade, ruptured posterior circulationFrom the 1Division of Neurosurgery, Department of Surgery and 2Institute of Medical
Science, Faculty of Medicine, University of Toronto, Toronto, Ontario; 3Division of
Neurosurgery, Department of Surgery, University of British Columbia, Vancouver, British
Columbia; and 4Division of Neurosurgery, St. Michael’s Hospital, Labatt Family Centre of
Excellence in Brain Injury and Trauma Research, Keenan Research Centre for Biomedical
Science, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
To whom correspondence should be addressed: Naif M. Alotaibi, M.D.
[E-mail: naif.alotaibi@mail.utoronto.ca]
*A list of the SAHIT collaborators is presented in the Appendix.
Citation: World Neurosurg. (2017) 98:308-313.
http://dx.doi.org/10.1016/j.wneu.2016.10.099
Journal homepage: www.WORLDNEUROSURGERY.org
Available online: www.sciencedirect.com
1878-8750/$ - see front matter ª 2016 Elsevier Inc. All rights reserved.
ROSURGERY, http://dx.doi.org/10.1016/j.wneu.2016.10.099
ORIGINAL ARTICLE
JUSTIN WANG ET AL. LOSS OF CONSCIOUSNESS IN SUBARACHNOID HEMORRHAGEaneurysm, larger aneurysm size, more subarachnoid blood
detected radiographically, presence of intraventricular and/or
intracerebral hemorrhage, and presence of comorbidities,
including hypertension, myocardial infarction, liver disease, or
previous SAH.3,4
Loss of consciousness (LOC) is one of the most common pre-
senting symptoms in aneurysmal SAH and has been associated
with worse clinical grade, larger hemorrhages, global cerebral
edema, poor outcomes, and delayed cerebral ischemia (DCI).5-8
The largest study of LOC in SAH was reported in 2016 by
Suwatcharangkoon et al.,6 who retrospectively analyzed a
prospective series of 1460 patients with spontaneous SAH. An
important question that arose was in regard to how to separate
the effect of LOC from the patient’s presenting neurologic
grade, using the Hunt and Hess (H&H) or World Federation of
Neurosurgical Societies (WFNS) grading system.5 Since
high-grade patients (H&H 4e5; WFNS 4e5) have LOC by deﬁni-
tion, it may be of value to assess LOC in otherwise low-grade
patients to better assess its contribution to outcome after aneu-
rysmal SAH. This is also of particular importance in determining
the association between LOC and DCI following SAH.
Therefore, we aimed to examine the prognostic signiﬁcance of
LOC in patients with SAH, particularly in patients with good
neurologic grade in terms of functional outcome, mortality, and
SAH-associated complications, including DCI.
METHODS
Study and Patient Selection
We conducted our data search using the Subarachnoid Hemor-
rhage International Trialists (SAHIT) Repository, a combined
database of recent clinical trials and prospective patient data from
institutions worldwide on the topic of aneurysmal SAH.9,10 The
SAHIT Repository has provided data for a number of previous
studies of SAH.9-14 Our search included all studies in the re-
pository. Our inclusion criteria were as follows: 1) good neurologic
grade on admission, deﬁned as a WFNS or H&H grade 1e3; 2) the
presence or absence of LOC at ictus; and 3) data on functional
outcomes, as evaluated with the modiﬁed Rankin Scale, Glasgow
outcome scale (GOS), and/or extended GOS at different serial time
points.15
Because poor neurologic grade, deﬁned as WFNS or H&H grade
4e5, is a strong predictor of poor outcome, this acts as a notable
confounder when attempting to evaluate the role of LOC as an
independent prognostic factor.5,16 Furthermore, patients with a
poor neurologic grade are often unconscious by deﬁnition. A poor
neurologic grade is a one-time designation assigned to patients on
presentation, whereas LOC, depending on how it is deﬁned, can
occur before admission and at any time after initial presentation to
the hospital. Therefore, to control for this, we limited our analysis
to patients with a good neurologic grade on presentation as
deﬁned above.17-21
Only one dataset was eligible for our study in terms of meeting
our foregoing inclusion criteria. This dataset was from the British
Aneurysm Nimodipine Trial (BRANT), a double-blind, placebo-
controlled randomized trial of the effect of nimodipine in the
prevention of DCI reported by Pickard et al.22 The BRANT remains
one of the most highly cited works on aneurysmal SAH and hasWORLD NEUROSURGERY 98: 308-313, FEBRUARY 2017provided the basis for the current use of nimodipine post-SAH
as the standard of care.23 Details of the BRANT are summarized
below.
Clinical Assessment
A post hoc analysis was performed on the 554 patients enrolled in
the BRANT, recruited from 4 neurosurgical units in the United
Kingdom. A total of 1115 patients were initially admitted to
participating centers between June 1985 and September 1987 with
SAH diagnosed by lumbar puncture or computed tomography
scan. Patients who presented more than 96 hours after SAH were
excluded. Other exclusion criteria were pregnancy; major renal,
hepatic, or pulmonary disease; preexisting cardiac decompensa-
tion; myocardial infarction within the previous 6 months; age <18
years; prior SAH in the previous week resulting in coma; and
inability to obtain consent. Eligible patients were assigned a
WFNS neurologic grade and were randomized to receive either
placebo or 60 mg of nimodipine every 4 hours for 21 days. Study
endpoints were incidence of cerebral infarction, ischemic neuro-
logic deﬁcits, and outcome at 3 months after enrollment.22 LOC in
the BRANT-SAHIT dataset was broadly deﬁned as occurrence of
unresponsiveness at the onset of SAH.
Outcomes
The primary outcome for our post hoc analysis was the 5-point
GOS as a measure of functional outcome, with a score of 1e3
designated as unfavorable (i.e., death, vegetative state, and severe
disability precluding the ability to live independently, respec-
tively).22 Outcome assessment at the 3-month follow-up was
conducted in person by a physician not involved in the patient’s
initial early management or through mail or telephone interview if
a patient was directly unavailable or had relocated out of the
region.
Secondary outcomes were DCI, time to DCI, aneurysmal
rebleed, length of hospital stay, and time to death. Rebleed or DCI
in the trial was categorized as either “deﬁnitive” if conﬁrmatory
evidence of a bleed or infarct was present on computed tomog-
raphy scan, during surgery, or during autopsy, or “probable” if
based solely on clinical factors and suspicion. For our analysis,
only deﬁnitive evidence of DCI and rebleed were included.
Statistical Analysis
For analysis, we used a propensity score-matching algorithm with
LOC at the ictus of SAH as the dichotomous exposure cohort.
Covariates balanced between the 2 cohorts (LOC present vs. ab-
sent at ictus) included age, sex, history of hypertension, history of
cardiac disease, WFNS grade, motor deﬁcits, hypertension at
admission (deﬁned as systolic blood pressure 140/90 mmHg),
treatment cohort (placebo vs. nimodipine), and time from SAH to
aneurysm surgery. We used caliper matching in our analysis, with
caliper width equal to 0.25 times the standard deviation of the
logit of the propensity score, with a 1:1 match ratio between the
LOC present and LOC absent cohorts. Previous work by Austin has
shown that calipers of a width close to 0.2 minimizes the mean
squared error of the estimated treatment effect and eliminates bias
in the estimator to produce conﬁdence intervals (CIs) with the
appropriate coverage rates.24 Balance between the covariates in the
2 cohorts used in matching was assessed by plotting propensitywww.WORLDNEUROSURGERY.org 309
ORIGINAL ARTICLE
JUSTIN WANG ET AL. LOSS OF CONSCIOUSNESS IN SUBARACHNOID HEMORRHAGEscore distribution histograms. All statistical analyses were
performed using R statistical software.25 Continuous variables
were compared using a 2-tailed t test. Proportions were
compared using the Fisher exact test unless stated otherwise. A P
value <0.05 was considered to indicate statistical signiﬁcance.
RESULTS
Application of the propensity score-matching algorithm identiﬁed
a total of 336 patients, including 168 with LOC at the ictus of SAH
(LOC cohort) and 168 without LOC at the ictus of SAH (no-LOC
cohort). Table 1 presents the baseline characteristics of the 2
cohorts. There was no statistically signiﬁcant difference between
the cohorts in terms of age, sex, history of hypertension, history
of cardiac disease, WFNS grade, motor deﬁcits and
hypertension on admission, treatment with nimodipine (60 mg
every 4 hours) or placebo, and time from SAH to surgery
(aneurysm clipping).
The baseline characteristics of the patients in our analysis are in
keeping with previously reported demographics of aneurysmal
SAH in terms of average age and female predominance.26 The
majority of patients (69% in each cohort) presented in WFNS
grade 2, followed by WFNS grade 3 (30% in each cohort). OnlyTable 1. Baseline Patient Characteristics Stratified by LOC at
Ictus
Variable
LOC at Ictus
Present
(n [ 168)
Absent
(n [ 168)
Age, years, mean  SD 49.8  11.7 47.4  12.4
Sex, number (%)
Male 64 (38.1) 62 (36.9)
Female 104 (61.9) 106 (63.1)
History of hypertension, number (%) 22 (13.1) 14 (8.3)
History of cardiac disease, number (%) 3 (1.8) 3 (1.8)
WFNS grade, number (%)
I 2 (1.2) 2 (1.2)
II 116 (69.0) 116 (69.0)
III 50 (29.8) 50 (29.8)
Motor deficits at admission, number (%) 19 (11.3) 12 (7.1)
Hypertension at admission, number (%) 25 (14.9) 19 (11.3)
Treatment group, number (%)
Placebo 88 (52.4) 80 (47.6)
Nimodipine 80 (47.6) 88 (52.4)
Proven aneurysm on angiography, number (%) 126 (75.0) 129 (76.7)
Time from SAH to aneurysm surgery, days
(median, IQR)
7 (5e11) 8 (5e15)
LOC, loss of consciousness; SD, standard deviation; WFNS, World Federation of Neuro-
surgical Societies; SAH, subarachnoid hemorrhage; IQR, interquartile range.
310 www.SCIENCEDIRECT.com WORLD NEU2 patients in each cohort were classiﬁed as WFNS grade 1.
Motor deﬁcits were uncommon in both cohorts, and the rate
did not differ signiﬁcantly between cohorts (11% in the LOC
cohort vs. 7% in the no-LOC cohort). Approximately one-half of
the patients in each cohort received nimodipine, and the other
half received placebo. The proportion of patients with
angiography-proven aneurysm was similar in the 2 cohorts.
Primary Outcomes
Table 2 presents data on our primary and secondary outcomes of
interest. The proportion of patients with poor outcome at 3
months (death, vegetative state, or severe disability) was
signiﬁcantly higher in the LOC cohort compared with the no-
LOC cohort (30% vs. 19%; odds ratio [OR], 1.78; 95% conﬁ-
dence interval [CI], 1.07e2.94; P ¼ 0.02). There was a trend to-
ward higher mortality in the LOC cohort, but the difference was
not statistically signiﬁcant (19% vs. 13%; OR, 1.54; 95% CI, 0.86e
2.7; P ¼ 0.14).
Secondary Outcomes
There was no statistically signiﬁcant difference in the incidence of
DCI between the 2 cohorts (20% in the LOC cohort vs. 18% in the
no-LOC cohort; OR, 1.16; 95% CI, 0.67e2.01; P ¼ 0.677). DCI
occurring early after SAH has been associated with worse out-
comes; however, there was no signiﬁcant difference in the time to
DCI between the 2 cohorts. Similarly, there was no statistically
signiﬁcant difference in the aneurysm rebleed rate between the 2
cohorts (10% in the LOC cohort vs. 9% in the no-LOC cohort; OR,
1.14; 95% CI, 0.54e2.83; P ¼ 0.853).
Both cohorts had a comparable median time to death (12 days in
the LOC cohort vs. 10 days in the no-LOC cohort). Similarly, there
was no signiﬁcant difference in the duration of hospital stayTable 2. Primary and Secondary Outcomes for Patients
Stratified by LOC at Ictus
Variable
LOC at Ictus
P Value
Present
(n [ 168)
Absent
(n [ 168)
Primary outcomes, number (%)
GOS 1e3 51 (30.4) 33 (19.6) 0.023*
GOS 1 (mortality) 33 (19.6) 23 (13.7) 0.145
Secondary outcomes, number (%)
DCI 34 (20.2) 30 (17.9) 0.677
Time to DCI, days, median (IQR) 6 (5e9) 7 (4e11) 0.958
Rebleed, number (%) 17 (10.1) 15 (8.9) 0.853
Time to death, days, median (IQR) 12 (8e19) 10 (7e21) 0.451
Length of hospital stay, days,
median (IQR)
16 (11e22) 15 (10e22) 0.632
LOC, loss of consciousness; GOS, Glasgow outcome scale; DCI, delayed cerebral ischemia;
IQR, interquartile range.
*Denotes significance at P < 0.05.
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no- LOC cohort).
DISCUSSION
Our ﬁndings show that LOC at the ictus of SAH is associated with
worse functional outcomes, as evaluated by the GOS at 3 months
post-SAH. There was also a trend toward increased mortality in the
LOC cohort. Previous studies have shown that LOC following SAH
has been associated with worse H&H and WFNS neurologic grades,
increased frequency of pulmonary edema, and worse left ventricular
function. Radiographically, LOC has been associated with increased
cisternal and intraventricular blood, global cerebral ischemia,
intraparenchymal blood, hydrocephalus, and acute cerebral infarct.
In terms of outcome, more patients in the LOC cohort had poor
functional outcome scores compared with the no-LOC cohort at the
3-month and 12-month follow-ups after discharge.6
Of note is our ﬁnding of no association between LOC at ictus
and the development of DCI. This is contrary to a previous study
reported by Hop et al.8 in 125 patients, which found an increased
risk of DCI in patients who experienced LOC for >1 hour after
SAH. A potential confounding factor in the Hop et al. study may
have been the inclusion of patients with a poor neurologic grade
(i.e., WFNS 4 or H&H 4) on presentation, because these
patients may be considered unconscious by deﬁnition, and a
worse clinical grade is a known independent risk factor for the
development of subsequent DCI. Nonetheless, our results are in
agreement with results reported by Suwatcharangkoon et al.6 in
a retrospective analysis of 1460 patients with SAH, which also
failed to ﬁnd an association between LOC and subsequent DCI
after controlling for other prognostic variables, including age,
neurologic grade on admission, aneurysm size, and
physiological derangements on admission, such as hypertension.
The cause of LOC in SAH has been thought to be associated
with decreased cerebral perfusion pressure (CPP) in the face of
increased intracranial pressure (ICP).6,27 The mechanism of the
increased ICP in SAH has yet to be fully elucidated, but is thought
to be due to a combination of hemorrhage volume, vasoparalysis,
and decreased cerebrospinal ﬂuid resorption.28 Similarly, the
development of hydrocephalus, seizures, and cardiopulmonary
dysfunction following SAH also may contribute to increased
ICP.5 Even transient decreases in CPP can cause global cerebral
ischemia, contributing to early brain injury (within 72 hours of
SAH ictus), believed to be a main contributor to morbidity
in patients with SAH.28 Various contributory apoptotic
cascades, including caspase-dependent and mitochondrial
caspase-independent pathways, have been implicated, leading to
disruption of the blood-brain barrier, brain edema, cell death, and
necrosis.5,28-30 The mechanism of early brain injury described
above in relation to LOC also has been thought to be pathophy-
siologically distinct in several ways from late or delayed injury dueWORLD NEUROSURGERY 98: 308-313, FEBRUARY 2017to vasospasm.29 This also may explain in part the lack of
association between initial LOC and the subsequent
development of DCI during the course of recovery.
Previous studies of LOC following SAH have all been subject to
the same limitation of suboptimal reliability in terms of accurate
reporting of LOC either by the patient himself or herself (partic-
ularly if he or she presents with a poor neurologic grade and is
stuporous or unreliable) or by witnesses. Although limited by
practicality, future studies should attempt to more accurately
assess the presence of LOC through collateral historians and
subsequently note the LOC of presenting patients at multiple,
different serial time points early on. This will also allow more
robust analysis of the true effect of varying durations of LOC on
outcome. In addition, a standardized deﬁnition of LOC needs to
be established to improve interobserver reliability. Patients in
whom a history of LOC is equivocal may be excluded. The per-
formance of early electrocardiographic and electroencephalo-
graphic monitoring may be able to better delineate the etiology of
LOC if caused by cardiac arrhythmias or epileptogenic activity.6
Additional work also may focus on the effects of SAH on the
brain, separating the direct cytotoxic effect of blood on the
brain and the indirect effects of increased ICP leading to
decreased CPP. The cellular mechanisms and pathways
associated with LOC and early brain injury, including the
identiﬁcation of molecular markers or targets for the potential
design of future therapeutics, remain to be further elucidated.
A main limitation of the present study is that our post hoc
analysis was done in patients recruited between 1985 and 1987 for
the BRANT. Care for patients with aneurysmal SAH has since
improved, with better outcomes reported in more recent studies.
Patient information, including clinical information on admission,
including the presence of confounders such as syncope, seizures,
or cardiac arrest, was limited. Furthermore, radiographic data on
the location and size of the aneurysms were unavailable. In
addition, the duration of LOC was not recorded completely.
CONCLUSION
Overall, our study reafﬁrms the prognostic role of LOC at the ictus
of aneurysmal SAH in portending poor outcomes. LOC may be an
indicator of early brain injury and an independent predictor of
poor neurologic outcome independent of the neurologic grade of
patients on presentation. Future directions should focus on
reﬁning the deﬁnition, veriﬁcation, and monitoring of LOC in
SAH and determining the association between the duration of
LOC and outcomes post-SAH.
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